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Abstract: Interval debulking surgery following neoadjuvant chemotherapy has become an alternative management 
for patients with advanced ovarian cancer. However, chemotherapy-induced alterations in cellular morphology may 
cause diagnostic difficulties for pathologists and inappropriate management by clinicians. We investigated the cyto-
morphological changes produced by chemotherapy in cytologic and tissue specimens of ovarian malignant Brenner 
tumors (MBTs). To the best of our knowledge, no data are available on the effect of chemotherapy on MBT cyto-
morphology. We analyzed cytological and histopathological features of MBT using scraping cytologic preparations, 
routine hematoxylin and eosin staining, and immunohistochemistry. We also described chemotherapy-induced cy-
tomorphological changes of MBT. Histopathological examination revealed one case with a substantially increased 
cytologic atypia, including extreme nuclear enlargement, marked nuclear pleomorphism, and multiple, prominent 
nucleoli. Necrosis or degenerative change was not evident. In contrast, another case displayed large coagulative 
tumor cell necrosis, hemorrhage, and fibrosis. Irregularly distributed islands, tumor cells in sheets or cords or scat-
tered individually were located adjacent to the necrotic areas. The individual tumor cells showed large, bizarre, 
degenerative-appearing nuclei with smudged or clumped chromatin. These cells had large amounts of dense, eo-
sinophilic cytoplasm with microvesiculation and macrovesiculation. Experiences with chemotherapy-induced cyto-
morphological changes of MBT have been limited. This study demonstrated the effect of chemotherapy on MBT 
cytomorphology. Preoperative chemotherapy is increasingly used to manage ovarian cancer. Therefore, pathologists 
should be aware of the morphological effects of chemotherapy.
Keywords: Chemotherapy, interval debulking surgery, malignant Brenner tumor, cytology
Introduction
Approximately 70% of ovarian cancers are not 
diagnosed until the disease involves the upper 
abdomen or has spread beyond the abdominal 
cavity [1]. Conventional treatment for advanced 
ovarian cancer is “optimal” debulking, which is 
aggressive cytoreductive surgery to remove all 
macroscopic lesions, and postoperative con-
current chemoradiation therapy, usually con-
sisting of a platinum-containing agent and a 
taxane, to achieve prolonged progression-free 
and overall survival [2, 3]. However, this aggres-
sive approach has 5-year overall survival rates 
of 10-20% in patients with FIGO stage IIIC (the 
most common stage of ovarian cancer) or IV 
diseases [4, 5]. For this reason, neoadjuvant 
chemotherapy was developed as an alternative 
therapeutic strategy for women with advanced 
ovarian cancer.
The principle of preoperative chemotherapy is 
administering chemotherapy before performing 
cytoreductive surgery [6, 7]. Researchers have 
reported dramatic clinical responses in patients 
who were too medically compromised to toler-
ate primary surgical cytoreduction. Improved 
diagnostic techniques have enabled clinicians 
to identify patients with advanced diseases 
who are unlikely to be optimally resected at ini-
tial surgery [7, 8]. Consequently, preoperative 
chemotherapy has gained popularity as a 
means of improving the physical and emotional 
trauma associated with initial ovarian cancer 
treatment [9]. 
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Neoadjuvant chemotherapy is being used at 
many institutions for preoperative manage-
ment of advanced ovarian cancers. Application 
of chemotherapeutic agents induces obvious 
cytomorphological changes in the cells of tumor 
tissues from patients who received chemother-
apy. Although the effects of chemotherapy on 
the cytomorphology of ovarian cancer cells 
have been reported, to the best of our knowl-
edge, no data are available on chemotherapy-
induced alterations in the cytomorphology of 
ovarian malignant Brenner tumors (MBTs). 
Little has been reported about cytomorphologi-
cal changes that may pose diagnostic difficul-
ties in the setting of known primary ovarian 
cancer. In this study, we summarize cytological 
and histopathological features of MBTs and 
describe morphological alterations induced by 
chemotherapy. Pathologists should be aware of 
this morphology because preoperative chemo-
therapy is likely to be used more frequently to 
manage advanced ovarian cancer.
Patients and methods
Patients and tissue specimens
From the surgical pathology files from 2013 to 
2015, 15 patients with Brenner tumors were 
identified: 4 had MBTs, 2 had borderline Bre- 
nner tumors, and 9 had benign Brenner tumors. 
Two of the four patients with MBT received che-
motherapy. Chemotherapy regimens varied 
among patients, but both received a carbopla-
tin and taxane. For comparison of histopatho-
logical features, all slides obtained from the 2 
cases of borderline Brenner tumor and the 9 
cases of benign Brenner tumor were also re- 
viewed. This study was reviewed and approved 
by the Institutional Review Board at Severance 
Hospital (2015-2225-001).
Scraping cytology preparation
Gross examination of biopsied and resected 
specimens was by thorough inspection and pal-
pation. Specimens were cut with a sharp knife 
into two or more pieces. If necessary, the cut 
surface was wiped to remove excess blood. The 
area thought to be most representative of the 
lesion was chosen by repeat inspection and 
was scraped with a sharp scalpel. The resulting 
semifluid drop was spread on a glass slide in 
the same manner as that of conventional fine-
needle aspiration cytology. Three to four slides 
from different representative areas were made 
for each sample. Slides were immediately put 
into 95% ethyl alcohol and stained with hema-
toxylin and eosin (H&E) and a modified 
Papanicolaou stain.
Histopathological examination
After cytology, specimens were fixed in 10% 
neutral-buffered formalin and embedded in 
paraffin blocks. From each formalin-fixed, par-
affin-embedded (FFPE) block, 4-μm sections 
were cut and stained with H&E, and prepared 
for immunohistochemical staining. All slides 
were examined under routine light microscopy 
by two independent pathologists.
Table 1. Antibodies used for immunohistochemical staining
Antibody Source Clone Dilution
p63 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA DAK-p63 1:150
CK5/6 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA D5/16 B4 1:200
PAX8 Cell Marque Corp., Rocklin, CA, USA Polyclonal 1:50
WT1 Cell Marque Corp., Rocklin, CA, USA 6F-H2 1:100
p16 Ventana Medical Systems, Inc., Tucson, AZ, USA E6H4 RTU
p53 NovoCastra Laboratories, Ltd,, Newcastle upon Tyne, UK DO-7 1:300
ER Thermo Fisher Scientific Inc., Fremont, CA, USA SP1 1:100
PR Dako, Agilent Technologies, Inc., Carpinteria, CA, USA PgR 636 1:50
CK7 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA OV-TL 12/30 1:100
CK20 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA Ks 20.8 1:100
CDX2 Cell Marque Corp., Rocklin, CA, USA EPR2764Y 1:400
CK5/6: cytokeratin 5/6; PAX8: paired box 8; WT1: Wilms tumor 1; ER: estrogen receptor; PR: progesterone receptor; CK7: 
cytokeratin 7; CK20: cytokeratin 20; CDX2: caudal type homeobox 2; RTU: ready-to-use.
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Immunohistochemistry
FFPE sections were deparaffinized and rehy-
drated with a xylene and alcohol solution. Im- 
munohistochemical staining used the Ventana 
Benchmark XT automated staining system 
(Ventana Medical Systems, Inc., Tucson, AZ, 
USA) or Dako Omnis (Dako, Agilent Technologies, 
Inc., Carpinteria, CA, USA) according to the 
manufacturer’s instructions. Antigen retrieval 
used Cell Conditioning Solution (CC1; Ventana 
Medical Systems, Inc.) or EnVision FLEX Target 
Retrieval Solution, High pH (Dako, Agilent 
Technologies, Inc.). Sections were incubated 
with primary antibodies (Table 1). After chromo-
genic visualization using ultraView Universal 
DAB Detection Kit (Ventana Medical Systems, 
Inc.) or EnVision FLEX/HRP (Dako, Agilent Te- 
chnologies, Inc.), slides were counterstained 
with hematoxylin and coverslipped. Appropriate 
positive and negative controls were stained 
concurrently to validate staining.
Results
Histopathology of benign and borderline 
Brenner tumors
Benign Brenner tumors had scattered, small, 
round-to-polygonal nests of urothelium-like epi-
thelial cells surrounded by dense fibrous stro-
ma (Figure 1A). Occasional microcysts appe- 
ared within the nests. The tumor cells had 
sharp outlines with polygonal, pale-to-eosino-
philic cytoplasm (Figure 1B). The tumor cells 
were relatively uniform in size with distinct cell 
borders. The tumor cell nuclei often had longi-
Figure 1. Histopathological findings of benign and borderline Brenner tumors. A. Low-power view of benign Brenner 
tumor. Well-demarcated nests of tumor cells are shown within dense fibrous stroma. B. High-power view of a benign 
Brenner tumor. The tumor cells contain round-to-oval nuclei without cytologic atypia. C. Low-power view of a border-
line Brenner tumor. The tumor cell nests are characteristically large and cystic, with papillary or polypoid protrusions 
into cystic spaces and more irregularly shaped than benign Brenner tumors. D. High-power view of a borderline 
Brenner tumor. Epithelial proliferation was higher for borderline than for benign Brenner tumor. The tumor cells 
show mild-to-moderate cytologic atypia, with nuclear enlargement and occasional mitotic figures (blue circles).
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tudinal grooves and small, inconspicuous nu- 
cleoli. No cytologic atypia or mitotic figures 
were found.
Borderline Brenner tumors showed several la- 
rge, irregular-shaped nests of tumor cells, most 
of which displayed cystic dilatation with intralu-
minal papillary or polypoid protrusions (Figure 
1C). The intervening stroma of borderline Bre- 
nner tumors was less obvious than for benign 
Brenner tumors. Prominent nuclear stratifica-
tion was noted. The degree of epithelial prolif-
eration was higher for borderline than benign 
Brenner tumors. Although most tumor cells 
showed mild cytologic atypia, some exhibited 
moderate atypia with nuclear enlargement and 
hyperchromasia. Three mitotic figures were de- 
tected in 10 high-power fields (Figure 1D). The 
morphological features of borderline Brenner 
tumors were similar to a low-grade urothelial 
carcinomas.
Histopathology of MBT
MBT cells were arranged in nests with irregular 
borders or showed a geographic, anastomosing 
or jigsaw pattern indicative of an invasive tumor 
(Figure 2A). Variably sized, irregularly shaped 
tumor cell nests were delineated by infiltrating 
borders with obvious stromal desmoplasia 
Figure 2. Histopathological, immunohistochemical, and cytological findings of MBT. A. Scanning view of MBT (case 
1). Variably sized, irregularly shaped nests of tumor cells are surrounded by dense collagenous stroma. These nests 
are separated by cleft-like retraction spaces from the stroma. B. Low-power view of MBT (case 1). The tumor cell 
nests are outlined by irregularly infiltrating borders and an obvious stromal desmoplasia. C. Low-power view of MBT 
(case 2). The tumor cells are predominantly in irregular or anastomosing cords 2-3 cells thick. D. Medium-power 
view of MBT (case 2). Irregular-shaped clusters and cords of tumor cells infiltrate the stroma. E. High-power view of 
MBT (case 2). The tumor cells have distinct borders and pleomorphic nuclei with hyperchromasia and conspicuous 
nucleoli. The cytoplasm is abundant and clear to eosinophilic. F-H. Immunohistochemical findings. The tumor cells 
react with F. p63, G. CK7, and H. CK5/6. I. Scraping cytologic preparation of MBT. The tumor cells are loosely ag-
gregated and irregularly distributed. They show abundant eosinophilic cytoplasm and large, hyperchromatic nuclei 
with coarse chromatin and one or more prominent nucleoli.
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(Figure 2B). Cleft-like retraction spaces sepa-
rated tumor nests from stroma. In some areas, 
the tumor cells with large, hyperchromatic nu- 
clei were arranged predominantly in cords that 
were 2-3 cells thick (Figure 2C). These cells had 
distinct borders with abundant, eosinophilic 
cytoplasm (Figure 2D). The tumor cell nuclei 
displayed marked pleomorphism and mem-
brane irregularity (Figure 2E). Twelve mitotic 
figures were observed in 10 high-power fields. 
Immunohistochemically, the tumor cells were 
strongly and uniformly positive for p63 (Figure 
2F), cytokeratin 7 (CK7; Figure 2G), and CK5/6 
(Figure 2H), but negative for PAX8, Wilms tumor 
1 (WT1), p16, p53, estrogen receptor (ER), pro-
gesterone receptor (PR), CK20, and caudal ty- 
pe homeobox 2 (CDX2). Densely packed, beni- 
gn-appearing stromal cells were arranged in a 
whirling or herringbone pattern and had small, 
ovoid-to-spindle-shaped nuclei.
Cytomorphology of MBT
Scraping cytologic smears were hypercellular, 
with scattered, irregularly shaped, loosely ar- 
Figure 3. Histopathological and cytological findings of chemotherapy-treated MBT. A. Low-power view of chemother-
apy-treated MBT (case 1). Similar to chemotherapy-naive MBTs, the tumor cell nests have jagged contours, infiltrate 
the stroma, and frequently anastomose. The stroma is densely fibrotic, but does not show necrosis or degenera-
tion. B. High-power view of chemotherapy-treated MBT (case 1). The tumor cells have substantial nuclear atypia. A 
marked nuclear enlargement, conspicuous, occasionally multiple cherry-red nucleoli, and increased membrane ir-
regularity are observed. Shown is a chromatin clearing with chromatin margination along the membrane. No coagu-
lative tumor cell necrosis or degenerative change is identified. C. Scanning view of chemotherapy-treated MBT (case 
2). Compared to Image A, Image C demonstrates large areas of coagulative tumor cell necrosis and hemorrhage. 
Some scattered clusters and cords of tumor cells (middle one-third) are adjacent to necrosis. D and E. High-power 
view of chemotherapy-treated MBT (case 2). Large, degenerative-appearing nuclei show coarse or smudged chro-
matin and a marked irregularity of the nuclear membrane. The tumor cell nuclei are 10-fold larger than surrounding 
stromal cells. Nucleus-to-cytoplasm ratio was decreased because of increased cell size. The cytoplasm is densely 
eosinophilic, with microvacuolation. Some tumor cells have large intracytoplasmic vacuoles and perinuclear halo-
like appearances. Cyst-like clear spaces are noted between the tumor cells.
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ranged clusters of tumor cells (Figure 2I). The 
tumor cells had relatively distinct cell borders 
and enlarged, hyperchromatic nuclei. Markedly 
pleomorphic, bizarre nuclei were occasionally 
detected. Most tumor cell nuclei showed hyper-
chromasia, membrane irregularity, and one or 
more prominent nucleoli. Mitoses were fre-
quently observed. The cytomorphological fea-
tures were consistent with those observed in 
MBT tissue sections. 
Histopathology of chemotherapy-treated MBT
We could examine two cases of chemotherapy-
treated MBT. In both cases, chemotherapy-
treated MBTs exhibited distinctive morphologi-
cal characteristics when compared with MBTs 
of the patients who did not receive chemother-
apy (chemotherapy-naive MBTs). Furthermore, 
there were obvious morphological differences 
between the two cases. Firstly, in case 1, low-
power views of chemotherapy-treated MBTs 
were similar to chemotherapy-naive MBTs, with 
the tumor cell nests in irregular, jagged arrange-
ments surrounded by desmoplastic stroma and 
retraction artifacts surrounding the nests 
(Figure 3A). By high-power views, the nuclei of 
chemotherapy-treated MBT cells were larger 
and had irregular nuclear membranes com-
pared to chemotherapy-naive MBTs. Obvious 
nuclear clearing with margination of chromatin 
along the nuclear membrane and multiple, 
prominent, cherry-red nucleoli were noted 
(Figure 3B). Mitotic figures were often observed, 
including a few atypical mitoses. The cytoplasm 
was either intensely eosinophilic or clear, with 
variably sized vacuoles. No coagulative tumor 
cell necrosis, hemorrhage, cholesterol clefts, 
fibrinous debris, or nuclear degenerative chan- 
ge was detected. The stroma showed a diffuse 
desmoplastic response, with moderate inflam-
matory infiltrate. Fine collagen fibrils were occa-
sionally admixed with reactive fibroblast-like 
cells. No thick collagen bundles or hyalinized 
fibrotic reactions were observed. 
Secondly, in case 2, large areas of coagulative 
tumor cell necrosis and hemorrhage were evi-
dent. Cords or clusters of surviving tumor cells 
were scattered and adjacent to necrotic areas 
(Figure 3C). Individual tumor cells had both 
nuclear and cytoplasmic alterations. Nuclear 
features included extreme enlargement with 
irregular outlines. In a few areas, the tumor cell 
nuclei were more than 10-fold larger than adja-
cent stromal cells (Figure 3D). Sometimes, the 
nuclei had such a bizarre outline that they mim-
icked multinucleated giant cells. Moreover, 
they appeared degenerated, with chromatin 
clumping or smudging. The cytoplasm was ab- 
undant and intensely eosinophilic. Aggregates 
of intracytoplasmic microvesicles resulted in a 
foamy appearance (Figure 3D). Some tumor 
cells had large intracytoplasmic vacuoles, 
resembling perinuclear haloes. Cyst-like spac-
es were observed between individual tumor 
cells (Figure 3E). Mitotic figures were rarely 
detected. The stroma was often densely fibrotic 
Figure 4. Scraping cytologic preparation of chemotherapy-treated MBT. A. The tumor cells have abundant, densely 
eosinophilic cytoplasm and large, pleomorphic nuclei. The cell border is relatively distinct. B. Pleomorphic nuclei 
are randomly distributed through a pool of abundant, densely eosinophilic cytoplasm that appears to be merged 
with each other. Note a significant variability in nuclear size and shape, accompanied by a low nucleus-to-cytoplasm 
ratio.
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and contained inflammatory cells, cholesterol 
clefts, and fibrinous debris.
Immunohistochemically, no significant change 
in the expression pattern was observed after 
chemotherapy. In both cases, the tumor cells 
were positive for p63, CK7, and CK5/6, but neg-
ative for PAX8, WT1, p16, p53, ER, PR, CK20, 
and CDX2.
Cytomorphology of chemotherapy-treated MBT
Scraping cytologic preparation showed moder-
ately cellular smears, with necrotic and hemor-
rhagic backgrounds. Several irregularly shaped 
cell clusters had large atypical cells with rela-
tively distinct cell borders and pleomorphic 
nuclei with coarse chromatin and conspicuous 
nucleoli (Figure 4A). Mitoses were infrequent. 
Abundant, dense eosinophilic cytoplasm mer- 
ged to form cytoplasmic pools (Figure 4B). 
Despite the nuclear enlargement, the increase 
in cytoplasm resulted in a low nucleus-to-cyto-
plasm ratio. These cytomorphological features 
were consistent with tissue sections from che-
motherapy-treated MBTs. 
Discussion
Preoperative chemotherapy is used to treat 
several cancers, including breast, lung, stom-
ach, and colorectal cancer [10-14]. Because of 
dramatic response rates to chemotherapy, 
interval debulking surgery after chemotherapy 
is also increasingly used to treat advanced 
ovarian cancers. Although some studies report-
ed the effects of preoperative chemotherapy 
on cellular morphology [10, 15-19], few studies 
have investigated morphological changes in 
chemotherapy-treated ovarian cancer. Three 
previous reports documented the morphologi-
cal effects of chemotherapy on ovarian cancer 
[15, 20, 21]. Chew and colleagues [15] report-
ed that the cytomorphological alterations in 
ovarian cancer paralleled changes in cancers 
of other organs. They observed significant alter-
ations in both nuclei (enlargement with mem-
brane irregularities, chromatin smudging and 
clumping, and overall degenerative appear-
ance) and cytoplasm (clear-to-foamy change 
due to microvesiculation and macrovesicula-
tion, eosinophilia, and granularity). McCluggage 
and colleagues [20] also found that the mor-
phological effects of chemotherapy on ovarian 
cancer are characterized by both nucleus 
(enlargement with extremely bizarre nuclear 
outlines and smudged or clumped chromatin) 
and cytoplasm (eosinophilia or clear cell change 
with a vacuolated or foamy appearance) Wang 
and colleagues [21] observed extensive tumor 
necrosis and surviving tumor cells in a back-
ground of fibrosis. The tumor cells that were 
individually scattered or arranged in cords and 
islands were approximately 3-4 times larger 
than non-enlarged tumor cells and had large 
amounts of eosinophilic cytoplasm with vacu-
oles. These observations indicate that histo-
logical grading of tumors, which has important 
prognostic implications and depends on the 
assessment of both cytological and architec-
tural features, is not reliable after chemothera-
py [20]. In addition, in tumors that respond well 
to chemotherapy, surviving cells with a clear, 
vacuolated cytoplasm may exist as individually 
scattered cells or small clusters of cells within 
a fibrotic stroma or areas of necrosis. These 
cells may be difficult to identify and, accord-
ingly, missed or misinterpreted as histiocytes. 
In this study, we investigated the effects of che-
motherapy on the cytomorphology of ovarian 
MBTs. To the best of our knowledge, chemo-
therapy-induced morphological alterations of 
MBT have not been documented. The morpho-
logical features we observed for MBTs treated 
with chemotherapy were similar to previous 
studies. Microscopically, one case revealed a 
substantially increased cytologic atypia includ-
ing nuclear enlargement, marked nuclear pleo-
morphism, and multiple, prominent nucleoli. No 
necrosis or degenerative change was observed. 
In contrast, another case had large coagulative 
tumor cell necrosis, hemorrhage, and fibrosis. 
The tumor cells in irregularly distributed islands, 
sheets or cords of tumor cells or individually 
scattered were located adjacent to necrotic 
areas. Individual tumor cells had large, bizarre, 
and degenerative-appearing nuclei with smu- 
dged or clumped chromatin. They had large 
amount of dense, eosinophilic cytoplasm with 
vesicles. Taken together, these results showed 
that careful morphological examination with or 
without the aid of ancillary techniques should 
help pathologists determine features that 
result from chemotherapy.
We further investigated cytomorphology of che-
motherapy-treated MBTs using scraping cyto-
logic preparations. Despite the wide applica-
tion of chemotherapy in cancer treatment, only 
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a few studies have investigated chemotherapy-
induced changes in cytological features using 
cytologic specimens. In a study by Albright and 
colleagues [22], radiation-treated lung cancer 
specimens had significantly decreased cellular-
ity, nuclear and cytoplasmic enlargement, nu- 
clear pyknosis and karyorrhexis, blurring of 
nuclear chromatin, and cytoplasmic vacuola-
tion. These alterations are similar to changes 
observed in tissue samples of other chemo-
therapy-treated malignancies. A significant 
decrease in the number of viable tumor cells 
after chemotherapy may create diagnostic 
challenges because of false-negative results 
for cytologic specimens from patients who 
received chemotherapy. A few studies com-
pared the sensitivity and specificity for frozen 
sections and touch-imprint cytology of sentinel 
lymph nodes from breast cancer patients [23-
26]. No significant differences were observed 
in sensitivity and specificity between the two 
modalities except for micrometastasis. Chemo- 
therapy did not affect the diagnostic accuracy 
of touch-imprint cytologic preparations [24]. 
Thus, assuming that the morphological fea-
tures of cytologic smears closely reflect histo-
logical appearances is reasonable. In this st- 
udy, we observed substantial changes in the 
cytological characteristics of MBTs using scrap-
ing cytologic smears. We observed several 
clusters of tumor cells scattered in a necrotic 
background with markedly pleomorphic nuclei, 
coarse chromatin, and conspicuous nucleoli. 
Abundant eosinophilic cytoplasm merged to 
create cytoplasmic pools. A concomitant incre- 
ase in the amount of nucleus and cytoplasm 
resulted in a low nucleus-to-cytoplasm ratio. 
These cytomorphological features were consis-
tent with observations of tissue sections. 
The histopathological and cytological features 
induced by chemotherapy might be considered 
in differential diagnoses. First, extensive coag-
ulative tumor cell necrosis and a relatively 
small amount of residual tumor tissue observed 
in ovaries raises the concern of metastatic car-
cinoma from the gastrointestinal tract. Meta- 
static tumor tissue from the gastrointestinal 
tract typically shows variable amount of cyto-
plasmic mucin, most primary ovarian cancers 
do not contain mucin. Furthermore, metastatic 
tumor cells from the gastrointestinal tract do 
not usually have bizarre, hyperchromatic nuclei 
and large amount of vacuolated cytoplasm. In 
contrast, these cytologic features were charac-
teristic of chemotherapy-treated ovarian can-
cers. In those cases, immunohistochemistry 
was useful for confirming the histopathological 
diagnosis. The most useful panels are p63, 
CK5/6, CK7, CK20, CDX2, PAX8, WT1, p53, 
p16, ER, and PR. Ovarian MBTs are positive for 
p63, CK5/6, and CK7. Ovarian high-grade 
serous carcinomas are positive for PAX8, WT1, 
ER, p53, and p16. In contrast, both MBTs and 
high-grade serous carcinomas are negative for 
CK20 and CDX2. The reverse is true for gastro-
intestinal carcinomas. In particular, colo- 
rectal carcinomas are strongly and uniformly 
positive for CK20 and CDX2, but negative for 
PAX8, WT1, ER, and PR. Second, abundant, 
vacuolated cytoplasm in tumor cells suggests 
clear cell carcinoma. Based on both previous 
data and our observations, high-grade serous 
carcinomas and MBTs showed variations in the 
amount of cytoplasmic vacuoles or clear cyto-
plasm after chemotherapy [21]. Comparison 
with pre-chemotherapy findings may readily 
resolve this issue. Immunoreactivity for p63 
and CK5/6 can differentiate MBT from clear 
cell carcinoma. MBT cells diffuse, strong expre- 
ssion for both p63 and CK5/6, but clear cell 
carcinoma neither reacts with p63 nor CK5/6. 
Similarly, WT1 and p53 are reliable biomarkers 
for differentiating clear cell carcinoma from 
high-grade serous carcinoma. Clear cell carci-
noma cells have no WT1 expression and patchy 
p53 expression, while high-grade serous carci-
nomas usually have diffusely positive WT1 and 
p53 staining. 
In conclusion, this study investigated the mor-
phological alterations of chemotherapy-treated 
MBTs using tissue and cytologic specimens. 
The samples showed morphological alterna-
tions to that were similar to observations from 
other types of chemotherapy-treated malignan-
cies. Cytomorphological features of chemother-
apy-treated MBTs observed in scraping cyto-
logic preparations were consistent with the 
tissue sections. As preoperative chemotherapy 
is increasingly used to treat advanced ovarian 
cancer, pathologists should recognize the asso-
ciated morphological changes, which may cre-
ate diagnostic challenges for determining histo-
logic type and grade and identifying residual 
malignancy. A thorough gross and microscopic 
examination of post-chemotherapy tumor spec-
imens is required with ample sectioning to 
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identify small amounts of residual, viable tumor 
cells.
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